<![CDATA[Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC]]>
RegulatoryapprovedbelzutifanlenvatinibPositive
AI Analysis
Summary
The FDA approved belzutifan plus lenvatinib combination for adults with advanced clear cell renal cell carcinoma, supported by Phase 3 LITESPARK-011 trial data.
Clinical Trial Data
Phase
Phase 3
Outcome Details
FDA approval of belzutifan plus lenvatinib combination for adults with advanced clear cell renal cell carcinoma
Importance:8/10
Sentiment:
0.90
FDA approvaloncologycombination therapyrenal cell carcinomaLITESPARK-011
Read the original article
Published by Cancer Network on September 24, 2026 7:29 PM